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Recent reports have detected the presence of iron in human atherosclerotic lesions [Biochem. J 286 (1992) 901-905]. This study provides evidence 
for a biochemical mechanism whereby iron is released from myoglobin by low density lipoprotein (LDL) which has become oxidised by the ferryl 
myoglobin species. The haem destabilisation a d iron release are inhibited by monohydroxamate compounds and desferrioxamine through their 
ability to inhibit the propagation of LDL oxidation. Thus, iron may derive from the myoglobin released from ruptured cells in the oxidising 
environment of the atherosclerotic lesion. 
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1. INTRODUCTION 
The mechanisms underlying the oxidation of low den- 
sity lipoproteins (LDL) in the artery wall [2] are yet to 
be elucidated. Evidence has been provided that a range 
of cell types capable of generating superoxide radicals 
induce the oxidation of LDL in culture, particularly 
macrophages/monocytes [3], smooth muscle cells [4] 
and endothelial cells [5], but only in iron-containing 
media [6]. Superoxide radical and hydrogen peroxide, 
its dismutation product, are not reactive per se with 
polyunsaturated fatty acids, but their reactivity may be 
amplified by interaction either with available transition 
metal ions, such as iron or copper, generating the hy- 
droxyl radical [7], or with specific peroxidases, uch as 
myoglobin [8 13] and haemoglobin [14,15], producing 
the ferryl forms of the haem proteins. 
In this study we have investigated the comparative 
mechanisms by which metmyoglobin and its activated 
counterpart, ferryl myoglobin, enhance LDL oxidation 
and how the oxidised LDL influences the reactivity and 
stability of the haem protein. Analysis of the propensity 
for the novel monohydroxamate compound, N-methyl- 
N-hexanoyl hydroxamate (NMHH) [16] to inhibit the 
oxidative modification of LDL compared with the 
trihydroxamatate, desferrioxamine (DFO), have af- 
forded interpretation of their comparative modes of ac- 
tion in terms of the inhibition of the initiating species 
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or chain-breaking scavenging of propagating lipid per- 
oxyl radicals. The results how that, on oxidation medi- 
ated by ferryl myoglobin, the resulting oxidised LDL 
attacks the haem protein, destabilising the haem ring, 
inducing haem destruction and iron release. NMHH 
and DFO inhibit the release of iron by suppressing LDL 
oxidation through the reduction of the initiating species, 
as well as by acting as inhibitors of the propagation of 
lipid peroxidation. During metmyoglobin-induced 
propagation of LDL oxidation under comparative con- 
ditions of interaction, the LDL oxidation is less exten- 
sive and iron is not made available. 
2. MATERIALS AND METHODS 
Desferrioxamine mesylate (desferal; DFO) was from CIBA-Geigy; 
NMHH was synthesized using standard literature methods [17]. Hy- 
drogen peroxide was of Aristar grade, and all other chemicals were of 
Analar grade and supplied by Merck (Darmstadt, Germany) or Sigma 
(Poole, UK). Myoglobin (ferric from, horse heart, type III) was pre- 
pared as described previously [18] and purified by oxidation with 
potassium ferricyanide and subsequent separation on a Sephadex G- 
15 column. Visible spectroscopy was performed on a Beckman DU-65 
spectrophotometer fitted with Quant 1 software. Incubations of 
metmyoglobin (final concentration 20/.tM) were carried out in 10 mM 
phosphate-buffered saline, pH 7.4, and spectra were run at timed 
intervals for up to 1.5 h. The concentration f the different myoglobin 
species were estimated by applying the extinction coefficients for fer- 
ryl, met- and oxymyoglobin [13]. 
Fresh human blood was obtained from human volunteers (with 
informed consent). LDL was prepared from the fresh plasma in a 
Kontron 2070 ultracentrifuge fitted with a fixed-angle Kontron rotor, 
according to the method of Chung et al. [19], as described previously 
[15]. The concentration of protein was determined by a modified 
procedure of [20]. LDL (final concentration 0.25 mg/ml protein) was 
reacted with metmyoglobin (20 ,uM) in phosphate-buffered saline at 
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Fig. 1. Altered electrophoretic mobility of LDL (0.25 mg/ml LDL 
protein) induced by myoglobin (20 HM + 25/~M H202) after 1.5 h 
incubation, and its inhibition by hydroxamates. Lanes 1,8, native 
LDL; lanes 2,3, LDL + metmyoglobin or ferryl myoglobin, respec- 
tively; lanes 4,6, LDL + metmmyoglobin + DFO (10¢tM) or NMHH 
(10 ,uM); lanes 5,7, LDL + ferryl myoglobin + DFO (10 ¢tM) or 
NMHH (10 ¢tM). 
pH 7.4 in the absence, as well as in the presence, of hydrogen peroxide 
(myoglobin : H202 = 1 : 1.25 mol ratio) to initiate ferryl myoglobin 
radical formation. Oxidative modification of the LDL was assessed by 
measuring the increased electrophoretic mobility on agarose gels 
(Beckman paragon lipo electrophoresis system) stained with Sudan 
black B stain. The extent of lipid peroxidation was assayed using a 
modified thiobarbituric acid assay [21] with the absorbance of the 
chromophore measured at 532 nm, corrected for background absorb- 
ance at 580 nm due to possible contributions from haem compounds, 
and incorporating appropriate controls [22]. Observations of the ef- 
fects of LDL on the oxidation state of myoglobin as a function of time 
were measured as difference spectra with prior subtraction ofthe LDL 
spectrum. 
The concentration ofchelatable iron was determined by low temper- 
ature (30 K) EPR spectroscopy using a Bruker ESP300 spectrometer 
fitted with a TEl03 rectangular cavity and an Oxford instruments 
liquid helium flow cryostat ESR900. Spectra were baseline-corrected 
by subtraction of a cavity spectrum or water/buffer under identical 
conditions. To allow accurate comparative quantitation, the chelata- 
ble iron was always converted to ferrioxamine prior to freezing. To 
accomplish this, DFO was either present already in the experiment or 
added 1 min prior to freezing the sample in the EPR tube. To deter- 
mine the absolute concentration ofDFO chelatable iron in the sample, 
the size of the g = 4.3 EPR signal from ferrioxamine was compared 
to a standard curve, constructed by adding varying amounts of ferrous 
sulphate to an aerobic solution of DFO (note: desferrioxamine cannot 
chelate iron out of undamaged haem proteins, such as myoglobin). 
3. RESULTS 
To investigate the potential  for release of  iron from 
the haem protein on interaction with LDL  the effects of  
ferryl myoglobin as an init iating oxidising species, and 
the propagat ion effects of  metmyoglobin,  were studied. 
After 90 min interaction both metmyoglobin and, to a 
greater extent, ferryl myoglobin cause an increase in the 
relative electrophoretic mobi l i ty of  the LDL,  indicating 
oxidat ion and change in the surface charge of  the LDL  
protein (Fig. 1). The level of  th iobarbitur ic  acid-reactive 
compounds,  as a measure of  breakdown products of  
l ipid peroxidat ion,  mediated by metmyoglobin and fer- 
ryl myoglobin,  reached 6.9 + 0.5 nmol/mg LDL  protein 
(corresponding to A532-A58 o0.69/mg LDL  protein) and 
40 __ 1.0 nmol/mg LDL  protein, respectively, at 1.5 h 
(n = 8). 
Changes in the oxidat ion state as the haem protein is 
act ivated by hydrogen peroxide in the presence and 
absence of  LDL  are shown in Fig. 2. The difference 
spectra were analysed for the presence of  ferryl myo- 
globin applying the Whi tburn  algorithms. Act ivat ion of 
metmyoglobin i the absence of  the LDL  substrate gen- 
erated ferryl myoglobin to the extent of  60% of the total 
haem, with very little change after 90 min interaction 
(Fig. 2, panels a), as previously reported [23]. In the 
presence of  LDL  the maximal  ferryl format ion is at- 
tained more rapidly and the actual level is enhanced 
initially, 72% by 6.5 min interaction, sustained up to 
14.5 min, but declines progressively as the reaction with 
LDL  continues, becoming progressively reduced to 
metmyoglobin with only 39% ferryl myoglobin remain- 
ing after 90 min interaction. 
Interact ion between LDL  and metmyoglobin in the 
absence of  hydrogen peroxide showed no detectable 
changes in the optical spectrum of the haem protein. 
The oxidative modif icat ion of  the LDL  is shown clearly 
both in terms of  l ipid peroxidat ion and altered surface 
charge, and is evidence for metmyoglobin-mediated 
propagat ion  of  oxidation. 
Pretreatment of  myoglobin with monohydroxamate  
and t r ihydroxamate hydrogen-donat ing compounds 
prior to activation with hydrogen peroxide (in the ab- 
sence of  LDL)  substantial ly inhibited the development 
of  the ferryl myoglobin (Fig. 2). In the presence of  LDL,  
pretreatment with NMHH (100/ IM) was more effective 
at reducing the ferryl myoglobin back to the met state 
than DFO when at concentrat ions in excess of  the 
myoglobin but not at lower concentrat ions (10/ IM).  At  
hydroxamate concentrat ions of  l0 / IM ,  both DFO and 
NMHH inhibited the oxidat ion of  LDL,  as shown by 
the suppression of  the altered electrophoretic mobi l i ty 
(Fig. 1), the monohydroxamate  being more effective 
than the tr ihydroxamate.  At  excess concentrat ions of  
both drugs (100/ IM)  the change in surface charge is 
total ly inhibited. 
Inhibit ion of  peroxidat ion of  the polyunsaturated 
fatty acyl chains of  the LDL  by the drugs when present 
at the time of  activation to ferryl myoglobin in the 
presence of  the LDL  is shown in Table I. At  l0 / IM  
levels, the monohydroxamate  was almost as effective as 
100 ¢tM concentrations, but 10 ¢lM DFO only inhibited 
to the extent of  60%. Metmyoglobin- induced propaga-  
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Fig. 2. Changes in the oxidation state as metmyoglobin is activated to ferryl myoglobin in the absence (A) and presence (B) of LDL and the effects 
of hydrogen-donating compounds. Panels a, no drugs; panels b, + DFO 10 pM (O), 100 ,uM (V); panels c, + NMHH 10 HM (O), 100/IM (V). 
Reaction concentrations: [metmyoglobin] 20/IM, [hydrogen peroxide] 25 ,uM, [LDL] 0.25 mg/ml, [hydroxamates] 10/~M, 100 HM. 
tion of oxidation was again inhibited extensively by 100 
/.tM monohydroxamate, but, in this case, 100/IM and 
10 HM DFO were only effective to 55% and 30% inhibi- 
tion, respectively. 10/IM NMHH is twice as effective as 
DFO as a chain-breaking antioxidant of LDL oxida- 
tion. 
The stability of the haem ring of the myoglobin on 
interaction with LDL was assessed by studying the in- 
crease in non-haem iron by EPR spectroscopy and by 
calculating the decrease in the amount of haem remain- 
ing by visible spectroscopy applying the Whitburn algo- 
rithms, and from the intensity of the absorption maxi- 
mum in the Soret region applying the extinction coeffi- 
cient. The visible spectroscopic results reveal a decline 
in the total haem content of 25% after interaction of 
ferryl myoglobin with LDL with time of exposure up to 
90 min, whereas the haem ring remains intact when 
metmyoglobin was applied under the same conditions 
and when metmyoglobin s activated by hydrogen per- 
oxide in the absence of LDL (data not shown). Confir- 
mation of the iron release from ferryl myoglobin conse- 
quent to its interaction with LDL is also provided from 
experiments applying low temperature EPR spectros- 
copy (Fig. 3) from the g-values at 6 and 4.3, respectively 
[24]. After the 90 min interaction between ferryl myo- 
globin and LDL, 25% of the original total haem was 
detected as non-haem iron; thus after this duration of 
interaction, the loss of haem is stoichiometric with the 
detection of non-haem iron. In the case of metmyo- 
globin as pro-oxidant, where the LDL oxidation was 
much less extensive, no non-haem iron was detected 
after 90 min of exposure to LDL (data not shown). This 
former finding supports the contention that, on oxida- 
tion by ferryl myoglobin, the oxidised LDL attacks the 
haem protein, destabilising the haem ring and releasing 
the iron. The pre-treatment of LDL with the monohy- 
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Fig. 3. Low-temperature EPR spectrum showing iron release from myoglobin the presence ofLDL and ferryl myoglobin. Samples were frozen 
at the times indicated. DFO was added to chelate the released iron for identification. (Trace a) MetMb + H202 + DFO + LDL, time = 5 s; (trace 
b) MetmMb + H202 + LDL; DFO was added at the end of incubation at time = 90 min; (trace c) 50 ¢tM ferrioxamine (at one-tenth e gain of 
(a) and (b), thus depicting 5~M non-haem iron). Reaction concentrations: [MetMb] 20/IM, [H202] 25/gM, [DFO] 100/~M, [LDL] 0.25 mg/ml. 
EPR conditions: Sweep time 3G/s; microwave power 20 mW; microwave frequency 9.37 GHz; modulation amplitude 10 G; time constant 330 ms; 
signal is average of 2 scans; temperature 30K. Spectra (a) and (b) are displayed at 10-times the gain of (c). 
droxamate compound prior to exposure to ferryl myo- 
globin prevents the oxidation of LDL. Thus the haem 
ring is protected from destabilisation, and the release of 
iron is prevented. 
4. DISCUSSION 
Our previous studies suggested that ruptured my- 
ocytes under oxidative stress generate ferryl myoglobin 
radicals which damage the lipids of membranes [10]. In 
addition, haem proteins from ruptured erythrocytes 
have been shown to oxidise LDL in vitro via activation 
to the ferryl state [14], and to modify its recognition 
properties affording uptake by macrophages. This can 
be prevented by enhancing the antioxidant status of the 
LDL [251. 
The results reported here show that oxidised LDL, 
oxidatively modified by interaction of the LDL with 
ferryl myoglobin, can interact with the myoglobin de- 
stabilising the haem ring and inducing iron release. In 
the presence of hydroxamate compounds, the haem ring 
is protected and iron release does not occur due to their 
hydrogen-donating antioxidant properties. It has been 
reported by other workers that at levels of hydrogen 
peroxide in excesss of the haem protein, with prolonged 
exposure, destabilisation of the haem ring occurs and 
iron may be released [11]. This work demonstrates that 
under conditions of interaction between myoglobin and 
hydrogen peroxide (in the absence of LDL) in which 
destabilisation of the haem ring of the ferryl myoglobin 
does not occur, the additional presence of oxidised LDL 
augments the peroxide level and the haem ring is dis- 
rupted. 
There are two potential mechanisms by which myo- 
globin may promote the peroxidation of LDL. Firstly, 
ferryl myoglobin can initiate peroxidation of the poly- 
unsaturated fatty acid side chains by hydrogen abstrac- 
tion. Secondly, in the absence of hydrogen peroxide, 
metmyoglobin amplifies the propagation of the LDL 
peroxidation by catalysing the decomposition of trace 
amounts of preformed lipid hydroperoxides within the 
LDL, according to the mechanisms for haem-mediated 
decomposition of lipid hydroperoxides (Eqn. 1-3) [26]. 
LOOH + HX-Fe 3+ ~ LO" + HX-[Fe ~v = 0] 2 "4- H + (1) 
LOOH + HX-Fe 3+ ~ LOO" + HX-Fe 2+ + H + (2) 
LOOH + HX-Fe 2+ --) LO" + HX-Fe 3+ + OH-  (3) 
The alkoxyl and peroxyl radicals and the ferryl spe- 
cies formed as the haem iron species recycle, are capable 
of re-initiating further LDL peroxidation, although 
only a small proportion of the metmyoglobin cycling 
through the ferryl state is spectroscopically detectable 
by this mechanism. 
The ability of DFO and NMHH to function as hy- 
drogen donors [9,10,23,27-30], independently of their 
iron-chelating properties, and to protect he haem pro- 
tein from destabilisation by reducing the initiating spe- 
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cies, may be an important  contr ibutor  to the mechanism 
of  the hydroxamate-mediated inhibit ion of  ferryl myo-  
globin- induced oxidat ion of  LDL.  The hydroxamates  
may also inhibit the propagat ion  process by acting as 
chain-breaking ant ioxidants and intercepting the prop-  
agat ion phase of  LDL  oxidat ion by H donat ion to 
alkoxyl or peroxyl species. The results suggest that, 
when in excess, the monohydroxamate  is a more effi- 
cient inhibitor of  ferryl myoglobin format ion and hence 
its effectiveness in inhibit ing lipid peroxidat ion,  because 
of  its scavenging of  the initiator. DFO has a lower rate 
constant than NMHH for interaction with the ferryl 
myoglobin species [23] and thus is not so effective in 
directly reducing the latter; however, at hydroxamate  
concentrat ions well below that of  myoglobin,  DFO sup- 
presses the ferryl myoglobin species more effectively 
than it reduces lipid peroxidat ion,  suggesting that DFO 
is not acting as a chain-breaking ant iox idant  at these 
low concentrat ions. In fact, NMHH is more effective in 
inhibit ing metmyoglob in-mediated LDL  oxidat ion than 
DFO and is thus a more efficacious chain-breaking an- 
t ioxidant. Important ly,  since the hydroxamates  possess 
the dual activities of  ant ioxidant and iron-chelat ing 
properties, they also have the potential  to inhibit the 
format ion of  hydroxyl  radicals, which may be generated 
on release of  iron from the haem protein by oxidised 
LDL.  It is possible, in vivo, that haem proteins, leaking 
from ruptured cells, may be capable of  enhancing the 
oxidat ion of  LDL  which has penetrated the endothe- 
l ium of  the coronary vessels. This may occur by haem 
prote in-mediated decomposit ion of  LDL  hydroperox-  
ides which have already been oxidised by, for example, 
contact with neighbouring cells or the enzymatic activ- 
ity of  l ipoxygenases. As the level of  LDL  oxidat ion 
increases on pro longed interaction with the haem pro- 
Table I 
The percentage inhibition of myoglobin-mediated LDL oxidation by 
desferrioxamine (DFO) and N-methyl-N-hexanoyl hydroxamate 
(NMHH) 
% decrease in A532-Asso/mg LDL n 
protein 
Ferryl myoglobin 
100,uM DFO 94 + 3 8 
100/2M NMHH 95 + 2 8 
10/2M DFO 60+ 5 4 
10pM NMHH 90 + 6 4 
Metmyoglobin 
100pM DFO 55 + 12 6 
100,uM NMHH 89 + 5 8 
10pM DFO 30-+ 5 4 
10/2M NMHH 58 -+ 6 4 
Hydroxamates were added to LDL (0.25 mg/ml) prior to addition of 
metmyoglobin (20 pM) _+ hydrogen peroxide (25 pM) and incubated 
for 1.5 h at 37°C. Concentrations stated are final concentrations. 
tein, iron release may occur. Previous studies [31] have 
reported the destruct ion of  haem and the release of  
iron interaction of  LDL  with haemin, an oxidative de- 
naturat ion product  of  haemoglobin,  but only in the 
presence of  excessive hydrogen peroxide levels (10 or 
20-fold molar  excesses). At  these concentrat ions the 
presence of  oxidised LDL  is not necessary to drive the 
iron release. Recent analyses of  the contents of  human 
atherosclerot ic lesions [1] have suggested that this is a 
potential ly pro-ox idant  environment with the possible 
avai labi l i ty of  iron and copper. Our findings suggest a 
potential  mechanism whereby iron may be derived from 
myoglobin released from ruptured cells in advanced le- 
sions. 
Acknowledgements: We thank the British Technology Group and Brit- 
ish Heart Foundation for funding this study, and King's College, 
London, for providing the EPR facilities. 
REFERENCES 
[1] Smith, C., Mitchinson, M.J., Aruoma, O.I. and Halliwell, B. 
(1992) Biochem. J. 286, 901-905. 
[2] Steinberg, D., Parthasarathy, S. Carew, T.E., Khoo, J.C. and 
Witztum, J.L. (1989) N. Engl. J. Med. 320, 915 924. 
[3] Cathcart, M.K., Morel, D.W. and Chisolm, G.M. (1985) J. Leu- 
koc. Biol. 38, 341-350. 
[4] Morel, D.W., DiCorleto, P.E. and Chisolm, G.M. (1984) Arteri- 
osclerosis 4, 357 364. 
[5] Henriksen, T., Mahoney, E.M. and Steinberg, D. (1981) Proc. 
Natl. Acad. Sci. USA 78, 6499-6503. 
[6] Leake, D. and Rankin, S. (1990) Biochem. J. 270, 741 748. 
[7] Halliwell, B. and Gutteridge, J.M.C. (1990) Methods Enzymol. 
186, 1 85. 
[8] George, P. and Irvine, D.H. (1952) Biochem. J. 52, 51l 517. 
[9] Harel and Kanner, J. (1987) Free Rad. Res. Commun. 3, 309- 
317. 
[10] Turner, J.J.O., Rice-Evans, C., Davies, M.J. and Newman, 
E.S.R. (1991) Biochem. J. 277, 833-837. 
[1 l] Puppo, A. and Halliwell, B. (1988) Free Rad. Res. Commun. 4, 
415422. 
[12] Galaris, D., Sevanian, A., Cadenas, E. and Hochstein, P. (1990) 
Arch. Biochem. Biophys. 281, 163 169. 
[13] Whitburn, K.D., Shieh, J.J., Sellers, R.M., Hoffman, M.Z. and 
Taub, I.A. (1982) J. Biol. Chem. 257, 1860 1869. 
[14] Giulivi, C. and Davies, K.J.A. (1991) J. Biol. Chem. 265, 19453 
19460. 
[15] Paganga, G., Rice-Evans, C., Rule, R. and Leake, D. (1992) 
FEBS Lett. 303, 154-158. 
[16] Rice-Evans, C. and Davies, M.J. (1990) United Kingdom Patent 
Application No 9024820.4. 
[17] Ulrich, H. and Sayigh, A.R. (1963) J. Chem. Soc. 1098-1101. 
[18] Dee, G., Rice-Evans, C., Obeyeskera, S., Meraji, S., Jacobs, M. 
and Bruckdorfer, K.R. (1991) FEBS Lett. 294, 3842. 
[19] Chung, B.H., Wilkinson, T., Geer, J.C. and Segrest, J.P. (1980) 
J. Lipid Res. 221,284-317. 
[20] Markwell, M.A., Haas, S.M., Biever, L.L. and Tubert, N.E. 
(1978) Anal. Biochem. 87, 106-110. 
[21] Walls, R., Kumar, K.S. and Hochstein, P. (1976) Arch. Biochem. 
Biophys. 172, 463468. 
[22] Gutteridge, J.M.C. (1986) Free Rad. Res. Commun. 1, 173-184. 
[23] Green, E.S.R., Evans, H., Rice-Evans, P., Davies, M.J., Salah, 
N. and Rice-Evans, C. (1993) Biochem. Pharmacol. 45,357 366. 
[24] Palmer, G. (1985) Biochem. Soc. Trans. 13, 548 560. 
[25] Labeque, R. and Marnett, L. (1988) Biochemistry 27, 7960-7970. 
181 
Volume 326, number 1,2,3 FEBS LETTERS July 1993 
[26] Andrews, B., Paganga, G. and Rice-Evans, C. (1993) Biochem. 
Soc. Trans. 21 (in press). 
[27] Morehouse, K.M., Flitter, W.D. and Mason, R.P. (1987) FEBS 
Lett. 222, 24(~550. 
[28] Darley-Usmar, V.M., Hersey, A., Garland, L.G., Leonard, E 
and Wilson, M.T. (1989) in: Free Radicals, Disease States and 
Antiradical Interventions (Rice-Evans, C. ed.) pp. 183 200, 
Richelieu Press, London. 
[29] Rice-Evans, C., Okunade, G. and Khan, R. (1989) Free Rad. Res. 
Commun. 7, 45-54. 
[30] Hartley, A., Davies, M. and Rice-Evans, C. (1990) FEBS Lett. 
264, 145-148. 
[31] Balla, G., Jacob, H.S., Eaton, J.W., Belcher, J.D. and Vercellotti, 
G.M. (1991) Arteriosclerosis Thrombosis 11, 1700-1711. 
182 
